Contraceptive Drugs and Devices Market Rapid Growth By Leading Players Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Bayer AG, Mayer Laboratories, Inc., Cooper Surgical, Inc., Allergan Plc, Cipla Limited,. Merck & Co. Inc.,

In the U.S., contraceptives are covered under the commercial health insurance policies through Affordable Care Act (ACA). This has significantly reduced out-of-pocket expenses on oral contraceptive pills from 21.8% in 2011 to 3.6% in 2016. The newly formed Trump government stated to ensure the coverage of contraceptives and all essential abortion related services without any co-pays, co-insurance or deductibles.
The Global Contraceptive Drugs and Devices Market was valued at US$ 18,273.2 million in 2015 and is projected to expand at a CAGR of 7.8% during the forecast period 2018- 2026. Better accessibility to contraceptives and growing awareness among the populace about the various benefits and ease of use of such contraceptive is contributing towards the growth of contraceptives drugs and devices market.

Download PDF Brochure of This Business Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/368

The U.S. FDA approved Liletta, a hormonal IUD, in 2015. Liletta was already being marketed in the Europe before being approved in the U.S. The product is marketed in collaboration between the manufacturers – Allergan Plc and Medicines 360. The product is also promoted by Women's Health Alliance, an organization engaged in promoting high-quality affordable healthcare for women.  However, male contraceptive products are less available in market as compared to female contraceptives. Research and development is underway to create and commercialize new male contraceptive products. Vasalgel—a long acting non-hormonal contraceptive—is one such male contraceptive product in the research phase, funded by the Parsemus Foundation, which works to advance the innovative but neglected medical researches. Vasalgel demonstrated successful results in pre-clinical studies and is expected to enter clinical trials over the forecast period.

Reversible Inhibition of Sperm Under Guidance (RISUG) is another male contraceptive product under development and is currently in the phase 3 study in India. RISUG, invented by Prof. Sujoy K. Guha, Indian Institute of Technology (IIT), involves blocking the vas deferens with a gel that can be flushed out when contraception is no longer needed. Launch of such new products is expected to benefit the growth of global contraceptive drugs and devices market.

Market Dynamics

Demand for advanced contraceptive options such as IUD, injectables, implants and diaphragms is observed to be high globally. This is owing to growing awareness among the populace, availability of reimbursement and growing demand for long term contraceptive methods. Government promotes the use of IUD and implants i.e. long-acting contraceptives for better therapeutic effect and safety. Also, reimbursement schemes are made attractive for consumers to opt for these contraceptive methods.

Request For Customization Of This Business Research Report: https://www.coherentmarketinsights.com/insight/request-customization/368

Detailed Segmentation:

U.S. Contraceptives Drugs And Devices Market, By Product Type:
Contraceptive Drugs
Oral Contraceptive Pills
Contraceptive Injectables
Topical Contraceptives
Contraceptive Devices
Male Contraceptive Devices
Condoms
Female Contraceptive Devices
Female Condoms
Contraceptive Diaphragms
Contraceptive Sponges
Contraceptive Vaginal Rings
Intrauterine Devices
Hormonal
Copper-T
Subdermal Contraceptive Implants
Company Profiles
Teva Pharmaceutical Industries Ltd.*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Future Plans
Church & Dwight Co. Inc.
Reckitt Benckiser Plc
Pfizer, Inc.
Bayer AG
Mayer Laboratories, Inc.
The Female Health Company
Cooper Surgical, Inc.
Allergan Plc
Cipla Limited
Merck & Co. Inc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.